Saturday, Sep 24, 2022
International Finance
Featured Healthcare

Healthcare investor Quadria raises $595 mn in second fund closing

Quadria Capital fund
The amount raised in the second fund exceeded its initial target of $400 million

Singapore’s Quadria Capital has raised $595 million from its second fund, media reports said. The amount raised in the second fund exceeded its initial target of $400 million. Quadria Capital is an independent healthcare focused on Asia’s healthcare sector.

The company started its second fundraise in the third quarter of 2018, media reports said. The Overseas Private Investment Corporation (OPIC) had committed $150 million to Quadria Capital Fund II. OPIC was the US government’s development finance institution until its merger with Development Credit Authority (DCA). 

The firm specialises in growth capital investments in small cap and middle-size companies in the healthcare sector. According to Abrar Mir, managing partner of Quadria Capital, Asia’s healthcare sector is expected to reach $4.2 trillion over the next five years. The sector will grow at 12 percent annually, compared to 5 percent growth globally. 

Quadria Capital Fund II has made two investments into leading global healthcare companies, media reports said. Those healthcare companies are AKUMS Drugs & Pharmaceuticals and Asian Institute of Gastroenterology. 

AKUMS Drugs & Pharmaceuticals is India’s biggest pharma contract development and manufacturing organisation (CDMO). Asian Institute of Gastroenterology is the world’s largest gastric sciences hospital, which was established in collaboration with the Mayo Clinic Network.

Last August, it was reported that the International Finance Corporation (IFC) committed $25 million into Quadria Capital Fund II. In 2015, the company raised $300 million for its Fund I. Currently, it manages more than $1 billion in total capital — and has made over 20 investments in Asian countries. 

Leave a Comment

* By using this form you agree with the storage and handling of your data by this website.